{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:30:38Z","timestamp":1774053038129,"version":"3.50.1"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T00:00:00Z","timestamp":1674604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>This study's goal was to assess the short-term effect on body weight and multiple systems following intravitreal injections of ranibizumab and aflibercept for retinopathy of prematurity (ROP).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We retrospectively assessed infants with ROP who received intravitreal anti-vascular endothelial growth factor agents (VEGF) treatment at our hospital. They were classified into 2 groups based on the drugs administered: the intravitreal ranibizumab (IVR) group and the intravitreal aflibercept (IVA) group. The body weight (BW) gains for the pre-treatment week, the 1st week after treatment, and the 2nd week after treatment were compared for each group. Additionally, other parameters such as blood pressure, heart rate, oxygen concentration, volume of milk and output of urine at four time points were also measured. We used repeated measurement analysis of variance analyzed these data.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 95 preterm infants were recruited, including 51 cases in the IVR group and 44 cases in the IVA group. The BW gain for the 1st week after treatment was significantly lower than the pre-treatment week in each group (<jats:italic>P\u2009<\/jats:italic>&amp;lt;\u20090.05), while there was no decrease in weekly BW gain in the 2nd week after treatment compared with that pre-treatment week. Based on the comparison between groups, the BW gain in the IVR group was significantly higher than in the IVA group in the second post-treatment week. Repeated measurement analysis of variance showed that there were no significant differences in blood pressure, heart rate, oxygen concentration, volume of milk and output of urine in both groups over time.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>IVR and IVA could have a short-term inhibitive effect on body weight gain in infants after treatment for ROP, whereas there is no significant impact on other systems.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2022.1077137","type":"journal-article","created":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T09:27:16Z","timestamp":1674638836000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Short-term effects of intravitreal anti-vascular endothelial growth factor agents on body weight and multiple systems after treatment for retinopathy of prematurity"],"prefix":"10.3389","volume":"10","author":[{"given":"Jing","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingfei","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanna","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haoming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuyong","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/S0140-6736(13)60178-6","article-title":"Retinopathy of prematurity","volume":"382","author":"Hellstr\u00f6m","year":"2013","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1177\/1120672118770557","article-title":"Systematic review and meta-analysis of the negative outcomes of retinopathy of prematurity treated with laser photocoagulation","volume":"29","author":"Liang","year":"2019","journal-title":"Eur J Ophthalmol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","article-title":"Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial","volume":"132","author":"Geloneck","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e0129383","DOI":"10.1371\/journal.pone.0129383","article-title":"A systematic review and meta-analysis on the safety of vascular endothelial growth factor (VEGF) inhibitors for the treatment of retinopathy of prematurity","volume":"10","author":"Pertl","year":"2015","journal-title":"PLoS One"},{"key":"B6","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00417-017-3878-4","article-title":"Changes in systemic vascular endothelial growth factor levels after intravitreal injection of aflibercept in infants with retinopathy of prematurity","volume":"256","author":"Huang","year":"2018","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1167\/tvst.9.8.43","article-title":"Ranibizumab population pharmacokinetics and free VEGF pharmacodynamics in preterm infants with retinopathy of prematurity in the RAINBOW trial","volume":"9","author":"Fidler","year":"2020","journal-title":"Transl Vis Sci Technol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jaapos.2017.10.006","article-title":"Medical and developmental outcomes of bevacizumab versus laser for retinopathy of prematurity","volume":"22","author":"Kennedy","year":"2018","journal-title":"J AAPOS"},{"key":"B9","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1167\/iovs.14-15842","article-title":"Pharmacokinetics of bevacizumab and its effects on Serum VEGF and IGF-1 in infants with retinopathy of prematurity","volume":"56","author":"Kong","year":"2015","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e0261095","DOI":"10.1371\/journal.pone.0261095","article-title":"Effect of intravitreal bevacizumab for retinopathy of prematurity on weight gain","volume":"16","author":"Obata","year":"2021","journal-title":"PLoS One"},{"key":"B11","doi-asserted-by":"publisher","first-page":"E51","DOI":"10.1016\/j.ophtha.2021.05.031","article-title":"International classification of retinopathy of prematurity, third edition","volume":"128","author":"Chiang","year":"2021","journal-title":"Ophthalmology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1001\/jamapediatrics.2017.4838","article-title":"Comparing alternative ranibizumab dosages for safety and efficacy in retinopathy of prematurity: a randomized clinical trial","volume":"172","author":"Stahl","year":"2018","journal-title":"JAMA Pediatr"},{"key":"B13","doi-asserted-by":"publisher","first-page":"CD009734","DOI":"10.1002\/14651858.CD009734.pub3","article-title":"Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity","volume":"1","author":"Sankar","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial","volume":"394","author":"Stahl","year":"2019","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00417-015-2996-0","article-title":"Vascular endothelial growth factor plasma levels before and after treatment of retinopathy of prematurity with ranibizumab","volume":"254","author":"Zhou","year":"2016","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.ajo.2011.07.005","article-title":"Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity","volume":"153","author":"Sato","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s10384-021-00895-9","article-title":"Serum vascular endothelial growth factor, insulin-like growth factor-1 and aflibercept levels in retinopathy of prematurity","volume":"66","author":"Furuncuoglu","year":"2022","journal-title":"Jpn J Ophthalmol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.exer.2018.01.020","article-title":"The effect of a single anti-vascular endothelial growth factor injection on neonatal growth and organ development: in-vivo study","volume":"169","author":"Khalili","year":"2018","journal-title":"Exp Eye Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"L555","DOI":"10.1152\/ajplung.00408.2001","article-title":"Treatment of newborn rats with a VEGF receptor inhibitor causes pulmonary hypertension and abnormal lung structure","volume":"283","author":"Le Cras","year":"2002","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1016\/j.chest.2022.06.017","article-title":"Intravitreal bevacizumab is associated with prolonged ventilatory support in preterm infants with bronchopulmonary dysplasia","volume":"162","author":"Huang","year":"2022","journal-title":"Chest"},{"key":"B21","doi-asserted-by":"publisher","first-page":"123","DOI":"10.5830\/CVJA-2019-058","article-title":"Cardiovascular assessment after treatment for retinopathy of prematurity: a comparative study between anti-VEGF agent (aflibercept) and laser","volume":"31","author":"Cilsal","year":"2020","journal-title":"Cardiovasc J Afr"},{"key":"B22","doi-asserted-by":"publisher","first-page":"243","DOI":"10.2147\/IMCRJ.S258881","article-title":"Hypertension and ischemic stroke after aflibercept for retinopathy of prematurity","volume":"13","author":"Bazvand","year":"2020","journal-title":"Int Med Case Rep J"},{"key":"B23","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1097\/ICU.0b013e32834595d0","article-title":"Ranibizumab versus bevacizumab for the treatment of neovascular age-related macular degeneration","volume":"22","author":"Abouammoh","year":"2011","journal-title":"Curr Opin Ophthalmol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e0230678","DOI":"10.1371\/journal.pone.0230678","article-title":"Neurodevelopmental outcomes following intravitreal bevacizumab injection in Japanese preterm infants with type 1 retinopathy of prematurity","volume":"15","author":"Arima","year":"2020","journal-title":"PLoS One"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1038\/s41372-020-00884-9","article-title":"Neurodevelopmental outcomes following bevacizumab treatment for retinopathy of prematurity: a systematic review and meta-analysis","volume":"41","author":"Kaushal","year":"2021","journal-title":"J Perinatol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e91","DOI":"10.1111\/aos.14852","article-title":"Ranibizumab in retinopathy of prematurity\u2014one-year follow-up of ophthalmic outcomes and two-year follow-up of neurodevelopmental outcomes from the CARE-ROP study","volume":"100","author":"Stahl","year":"2022","journal-title":"Acta Ophthalmol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1053\/j.ajkd.2006.11.039","article-title":"Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis","volume":"49","author":"Zhu","year":"2007","journal-title":"Am J Kidney Dis"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.1077137\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T09:27:17Z","timestamp":1674638837000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.1077137\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,25]]},"references-count":27,"alternative-id":["10.3389\/fped.2022.1077137"],"URL":"https:\/\/doi.org\/10.3389\/fped.2022.1077137","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,25]]},"article-number":"1077137"}}